Your browser is no longer supported. Please, upgrade your browser.
Settings
NVLN Novelion Therapeutics Inc. daily Stock Chart
NVLN [NASD]
Novelion Therapeutics Inc.
Index- P/E- EPS (ttm)-7.41 Insider Own0.20% Shs Outstand19.80M Perf Week-9.37%
Market Cap59.40M Forward P/E- EPS next Y-2.53 Insider Trans0.00% Shs Float17.09M Perf Month-12.28%
Income-138.40M PEG- EPS next Q-0.71 Inst Own77.50% Short Float11.22% Perf Quarter-32.28%
Sales127.00M P/S0.47 EPS this Y-45.30% Inst Trans-3.96% Short Ratio25.04 Perf Half Y-29.74%
Book/sh-2.40 P/B- EPS next Y46.10% ROA-37.50% Target Price5.75 Perf Year-59.95%
Cash/sh2.02 P/C1.49 EPS next 5Y- ROE- 52W Range2.96 - 7.68 Perf YTD-3.85%
Dividend- P/FCF- EPS past 5Y-10.00% ROI-32.00% 52W High-60.94% Beta0.98
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin40.40% 52W Low1.46% ATR0.22
Employees180 Current Ratio1.30 Sales Q/Q-22.00% Oper. Margin-73.00% RSI (14)31.67 Volatility4.56% 5.76%
OptionableYes Debt/Eq- EPS Q/Q-44.70% Profit Margin- Rel Volume0.09 Prev Close3.02
ShortableYes LT Debt/Eq- EarningsAug 14 BMO Payout- Avg Volume76.59K Price3.00
Recom2.50 SMA20-11.82% SMA50-17.22% SMA200-24.96% Volume6,797 Change-0.66%
Feb-07-17Reiterated RBC Capital Mkts Sector Perform $13.50 → $10
Aug-07-18 08:43AM  Novelion Therapeutics: 2Q Earnings Snapshot Associated Press
08:30AM  Novelion Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-31-18 08:15AM  Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy GlobeNewswire +5.46%
Jul-03-18 08:30AM  Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors GlobeNewswire -5.78%
Jun-25-18 08:01AM  Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions GlobeNewswire
08:00AM  Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions GlobeNewswire
Jun-08-18 03:40PM  Should You Invest In The Healthcare Sector And Novelion Therapeutics Inc (NASDAQ:NVLN)? Simply Wall St.
Jun-01-18 08:13AM  MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy GlobeNewswire -7.38%
07:54AM  MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy GlobeNewswire
May-22-18 10:03AM  Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN) Simply Wall St. -5.12%
May-15-18 05:59PM  Former Aegerion sales rep charged with defrauding U.S. insurers Reuters
May-10-18 08:47AM  Novelion Therapeutics: 1Q Earnings Snapshot Associated Press -6.10%
08:30AM  Novelion Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-18-18 05:57PM  Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock? Simply Wall St.
Apr-02-18 09:27PM  Does Novelion Therapeutics Incs (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
Mar-31-18 06:01AM  Novelion Therapeutics Supports World Lipodystrophy Day GlobeNewswire
06:00AM  Novelion Therapeutics Supports World Lipodystrophy Day GlobeNewswire
Mar-15-18 07:33PM  Novelion Therapeutics reports 4Q loss Associated Press -7.38%
05:17PM  Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
05:10PM  Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital GlobeNewswire
Mar-01-18 10:30AM  Doctor pleads guilty as part of Aegerion drug misbranding probe American City Business Journals
Feb-28-18 03:04PM  Doctor admits disclosing patient info to drugmaker Aegerion Reuters -7.80%
07:01AM  Novelion Therapeutics Observes Rare Disease Day GlobeNewswire
07:00AM  Novelion Therapeutics Observes Rare Disease Day GlobeNewswire
Jan-30-18 05:51PM  Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals GlobeNewswire +8.08%
04:49PM  U.S. judge sentences Novelion's Aegerion in drug marketing case Reuters
07:00AM  Novelion's Aegerion faces sentencing in U.S. drug marketing case Reuters
Jan-24-18 04:01PM  Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review GlobeNewswire
Jan-10-18 03:32PM  How Should You Think About Novelion Therapeutics Incs (NASDAQ:NVLN) Risks? Simply Wall St.
Dec-22-17 12:45PM  Aegerion says judges rejection of $40M plea clouds future American City Business Journals -5.49%
11:09AM  Novelion unit asks U.S. judge to approve plea deal, cites money woes Reuters
Dec-15-17 04:15PM  Is Novelion Therapeutics Inc (NASDAQ:NVLN) Cheap And High Growth? Simply Wall St.
Dec-04-17 08:30AM  Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer GlobeNewswire
Nov-27-17 11:50AM  What Investors Should Know About Novelion Therapeutics Incs (NVLN) Financial Strength Simply Wall St. +5.31%
Nov-21-17 08:30AM  Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice GlobeNewswire -9.60%
Nov-10-17 05:35PM  Should You Buy Novelion Therapeutics Inc (NVLN)? Simply Wall St.
Nov-09-17 08:45AM  Novelion Therapeutics reports 3Q loss Associated Press
08:28AM  Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change GlobeNewswire
Nov-01-17 04:54PM  U.S. submits revised plea deal with Novelion's Aegerion to court Reuters
Oct-31-17 08:30AM  Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer GlobeNewswire
Oct-18-17 04:49PM  U.S. judge says he may reject plea deal with Novelion's Aegerion Reuters
Oct-12-17 09:15AM  Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D GlobeNewswire
Sep-26-17 07:30AM  Corporate News Blog - Novelion's Subsidiary Aegerion Pleads Guilty for Misbranding Juxtapid; Agrees to a Settlement of $40 Million ACCESSWIRE
Sep-25-17 04:17PM  Patient assistance charity says U.S. contacted it in probe Reuters
Sep-24-17 08:00AM  Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day GlobeNewswire
Sep-22-17 08:52PM  Novelion's Aegerion resolves U.S. drug probes for $40 mln Reuters
04:50PM  Aegerion finalizes $40M settlement, guilty plea in drug misbranding case American City Business Journals
03:36PM  Novelion's Aegerion resolves U.S. drug probes for $40 mln Reuters
01:20PM  SEC fines pharmaceutical company $4.1 million for misleading performance metric MarketWatch
Sep-15-17 08:30AM  Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology GlobeNewswire
Sep-11-17 08:30AM  Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors GlobeNewswire
Aug-08-17 09:32PM  Novelion Therapeutics reports 2Q loss Associated Press -12.26%
07:00AM  Novelion Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-02-17 08:30AM  Novelion Therapeutics Appoints Mark DiPaolo to Board of Directors GlobeNewswire
Jul-28-17 08:30AM  Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
Jun-26-17 08:30AM  Novelion Therapeutics Added to the Russell 3000® & Russell Microcap® Indexes GlobeNewswire -5.96%
Jun-12-17 08:30AM  Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association GlobeNewswire
Jun-01-17 04:01PM  Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D GlobeNewswire
May-09-17 07:00AM  Novelion Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
07:00AM  Investor Network: Novelion Therapeutics Inc. to Host Earnings Call Accesswire
May-05-17 09:00AM  Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology GlobeNewswire
May-03-17 04:15PM  Novelion Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire
Apr-25-17 09:15AM  Novelion Therapeutics Announces Presentation at the Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire
Apr-19-17 04:15PM  Novelion Therapeutics Request to Voluntarily Delist from the Toronto Stock Exchange Granted GlobeNewswire
Apr-04-17 04:10PM  Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society GlobeNewswire
04:10PM  Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
Mar-31-17 08:30AM  NOVELION THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
08:00AM  Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors GlobeNewswire
06:00AM  Novelion Therapeutics Observes World Lipodystrophy Day GlobeNewswire
Mar-30-17 04:17PM  NOVELION THERAPEUTICS INC. Files SEC form 10-K, Annual Report
04:15PM  Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society GlobeNewswire
Mar-15-17 07:28AM  Novelion Therapeutics reports 4Q loss Associated Press
07:28AM  Novelion Therapeutics reports 4Q loss
07:15AM  NOVELION THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or
07:00AM  Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results GlobeNewswire
Mar-13-17 04:15PM  Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 GlobeNewswire
Mar-08-17 04:05PM  Novelion Therapeutics Announces Presentation at the 29th Annual ROTH Conference GlobeNewswire
Mar-07-17 09:09AM  NOVELION THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:43AM  U.S. Patent Trial and Appeal Board Affirms Lomitapide Patents with Favorable IPR Decisions GlobeNewswire
Mar-01-17 04:05PM  Novelion Therapeutics Announces Presentation at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
04:05PM  Novelion Therapeutics Announces Presentation at the Cowen and Company 37th Annual Health Care Conference
Feb-28-17 08:05AM  Novelion Therapeutics Observes Rare Disease Day GlobeNewswire
Jan-23-17 08:45AM  Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency GlobeNewswire
Jan-18-17 04:41PM  5 Expensive Drugs That Could End Up in Trump's Crosshairs at Motley Fool
Jan-09-17 09:32AM  NOVELION THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events +8.06%
07:41AM  Novelion Therapeutics Reports Preliminary 2016 Net Product Sales and Provides 2017 Outlook GlobeNewswire
06:00AM  Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan GlobeNewswire
Jan-04-17 09:20AM  Novelion Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-27-16 04:03PM  NOVELION THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Sta
Dec-22-16 07:02AM  Novelion Therapeutics' Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy GlobeNewswire
07:00AM  Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy GlobeNewswire
Dec-19-16 07:03AM  Splits Calendar: Novelion splits before market open today (1:5 ratio)
Dec-16-16 05:10PM  NOVELION THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
05:00PM  Novelion Therapeutics Completes Reverse Stock Split GlobeNewswire
08:36AM  Novelion Therapeutics Subsidiary Launches JUXTAPID® (lomitapide) in Japan GlobeNewswire
Dec-13-16 01:04PM  NOVELION THERAPEUTICS INC. Financials
Dec-05-16 04:48PM  QLT INC/BC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securi
11:29AM  Novelion Therapeutics, Inc. :NVLN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
08:30AM  Aegerion Pharmaceuticals, a Subsidiary of Novelion Therapeutics, Enters into Agreement in Principle to Settle Class Action Shareholder Lawsuit GlobeNewswire
02:00AM  Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA® (lomitapide) GlobeNewswire
Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.